Home/Pipeline/Proprietary Solid Tumor CAR

Proprietary Solid Tumor CAR

Solid Tumors

Pre-clinicalActive

Key Facts

Indication

Solid Tumors

Phase

Pre-clinical

Status

Active

Company

Velvet Therapeutics

About Velvet Therapeutics

Velvet Therapeutics is pioneering a next-generation in vivo CAR therapy platform designed to overcome key limitations of current ex vivo CAR-T approaches. Its technology utilizes a polyasparagine nanoparticle and minicircle DNA polyplex to deliver CAR genes directly into immune cells within the body, offering a redosable, non-integrating, and potentially off-the-shelf solution. The platform exhibits lymphatic tropism to avoid the hepatic sink and is initially targeting solid tumors, with its first proprietary solid tumor CAR data presented in 2025. As a private, pre-clinical stage company, Velvet aims to simplify and broaden the application of CAR therapies across immune cell types.

View full company profile

Therapeutic Areas

Oncology Solid Tumors

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed